Vertex Pharmaceutical shares soared 15% Wednesday as Wall Street cheered the results of a late-stage study of its new cystic fibrosis drug, an experimental treatment that targets the underlying cause of the disease rather than …
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …
Global pharmaceutical sales are expected to grow by 5% to 7% in 2011, thanks to robust growth in emerging markets, especially China, as well as new innovative treatments, and despite patent expirations and budget pressures in t…